HSA
SNDX icon

Hussman Strategic Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

Hussman Strategic Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.84M Buy
+84,000
New +$1.75M 0.42% 112

Other funds holding SNDX

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
VIG
Vienna Insurance Group Warsaw, Poland $381M AUM 105.39% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
TIP
Torray Investment Partners Bethesda, Maryland $741M AUM 26.16% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Hussman Strategic Advisors's SNDX Position: Q2 2026 in Review

Hussman Strategic Advisors opened a new position in Syndax Pharmaceuticals (SNDX) in Q2 2026: 84,000 shares worth $1.84M. The stake represents 0.42% of the portfolio and ranks #112 among its holdings.

48 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Hussman Strategic Advisors held 84,000 shares of Syndax Pharmaceuticals worth $1.84M as of Q2 2026.
  • Syndax Pharmaceuticals was a new Hussman Strategic Advisors position in Q2 2026.
  • Syndax Pharmaceuticals made up 0.42% of Hussman Strategic Advisors's portfolio in Q2 2026, its #112 holding.
  • 48 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Hussman Strategic Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.